EUVIMEDEUVIMED entdecken
Crossref

Choosing the Better Statin: A Prospective Comparison of Rosuvastatin and Atorvastatin

Riputa Shourie, Tanveer Ahmad Khan, Shreshth Khanna, Anwar Habib, Nadisha Oberoi

International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)

DOI: 10.25258/ijcpr.18.7.85 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Riputa Shourie und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease and contributes substantially to global morbidity and mortality. It commonly coexists with hypertension and type 2 diabetes mellitus, thereby accelerating the development of cardiovascular complications. Statins remain the cornerstone of lipid-lowering therapy, with atorvastatin and rosuvastatin being among the most frequently prescribed agents. Although both drugs effectively reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk, comparative evidence from routine clinical practice in the Indian population remains limited.

Aim

To comparatively evaluate the efficacy, safety, tolerability, and treatment compliance of rosuvastatin and atorvastatin monotherapy in patients with dyslipidemia, including those with associated hypertension and/or type 2 diabetes mellitus, managed at a tertiary care hospital according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines. Materials and Methods: A prospective observational comparative study was conducted in the Departments of Pharmacology and Medicine at Hamdard Institute of Medical Sciences and Research (HIMSR) and Hakeem Abdul Hameed Centenary Hospital (HAHC), Jamia Hamdard, New Delhi. A total of 300 eligible patients with dyslipidemia were enrolled, of whom 291 completed the study, while nine patients were lost to follow-up. Participants received either rosuvastatin or atorvastatin monotherapy according to the treating physician's clinical judgment. Baseline demographic characteristics, cardiovascular risk factors, lipid profile parameters, fasting blood glucose, glycated haemoglobin (HbA1c), serum creatinine, blood urea, serum glutamic-pyruvic transaminase (SGPT), treatment compliance, and adverse drug reactions were assessed at baseline and during follow-up. Statistical analysis was performed using appropriate parametric and non-parametric tests, with p < 0.05 considered statistically significant.

Results

Among the 300 enrolled participants, 291 completed follow-up. Both rosuvastatin and atorvastatin produced significant improvements in serum lipid parameters during the study period. Rosuvastatin demonstrated greater reductions in total cholesterol and LDL cholesterol and achieved lipid targets in a higher proportion of patients, whereas atorvastatin showed comparable improvement in triglyceride levels. Both treatments were generally well tolerated, with adverse drug reactions being mild and consistent with the established safety profile of statins. Patient compliance remained satisfactory throughout the study.

Conclusion

Rosuvastatin and atorvastatin are both effective and well-tolerated treatment options for dyslipidemia. Rosuvastatin demonstrated comparatively greater efficacy in improving LDL cholesterol and overall lipid control, while maintaining a favourable safety profile. These findings support the use of rosuvastatin as an effective therapeutic option for achieving recommended lipid targets in patients with dyslipidemia, particularly those with associated cardiovascular risk factors.

Zitieren

APA

Shourie, R., Khan, T. A., Khanna, S., Habib, A., & Oberoi, N. (2026). Choosing the Better Statin: A Prospective Comparison of Rosuvastatin and Atorvastatin. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.85

Vancouver

Shourie R, Khan TA, Khanna S, Habib A, Oberoi N. Choosing the Better Statin: A Prospective Comparison of Rosuvastatin and Atorvastatin. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.85

BibTeX
@article{Shourie2026,
  author = {Shourie, Riputa and Khan, Tanveer Ahmad and Khanna, Shreshth and Habib, Anwar and Oberoi, Nadisha},
  title = {Choosing the Better Statin: A Prospective Comparison of Rosuvastatin and Atorvastatin},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {07},
  doi = {10.25258/ijcpr.18.7.85}
}
Kostenlos starten →